Skip NavigationSkip to Content
Return Return to Search Results

In vitro efficacy of immuno-chemotherapy with anti-EGFR human fab-taxol conjugate on A431 epidermoid carcinoma cells

  1. Author:
    Wang, X.
    Zhu, J.
    Zhao, P.
    Jiao, Y. G.
    Xu, N.
    Grabinski, T.
    Liu, C.
    Miranti, C. K.
    Fu, T.
    Cao, B. B.

  2. Author Address

    Nanjing Med Univ, Key Lab Antibody Technol, Nanjing, Peoples R China. Van Andel Res Inst, Lab Antibody Technol, Grand Rapids, MI USA. Jiangsu Province Ctr Dis Control & Prevent, Nanjing, Peoples R China. Nanjing Med Univ, First Affiliated Hosp, Dept Endocrinol, Nanjing, Peoples R China. Van Andel Res Inst, Lab Integrin Signaling & Tumorigenesis, Grand Rapids, MI USA. SAIC Frederick, Expt Immunol Lab, Frederick, MD USA.;Cao, BB, Nanjing Med Univ, Key Lab Antibody Technol, 140 Hanzhong Rd, Nanjing, Peoples R China.;brian.cao@vai.org
    1. Year: 2007
    2. Date: Jun
  2. Journal: Cancer Biology & Therapy
    1. 6
    2. 6
    3. Pages: 980-986
  4. Type of Article: Article
  5. ISSN: 1538-4047
  1. Abstract:

    The aims of this study were to generate a human Fab fragment against EGFR; conjugate it to paclitaxel (Taxol) as an immuno-chemotherapy agent; and investigate its in vitro anti-tumor efficacy on A431 epidermoid carcinoma cells. A431 cells (EGFR-positive), NIH 3T3 cells (EGFR-negative), and purified EGFR were used for subtractive panning or a human naive Fab phage library to generate a human anti-EGFR Fab fragment that binds the EGFR extracellular domain in native conformation and subsequently internalizes it into the cytosol. The Fab was then conjugated with the chemotherapeutic Taxol, and cell proliferation inhibition and apoptosis (TUNEL) assays were conducted to determine the effect of this Fab-drug conjugate on A431 cells. The specificity and internalization property of this Fab were characterized by immunoprecipitation fluorescence staining flow cytometry, and Hum-Zap assay. The binding affinity to purified EGFR was 30 nM The Fab-Taxol conjugate inhibited A431 cell proliferation at low concentrations and in c dose-responsive manner; more than 70% inhibition was observed at 52 pM. Furthermore almost 100% of cells underwent apoptosis after treatment with Fab-Taxol at 26 pM for, 48 hours. Our findings suggest that this Fab-Taxol conjugate could be a potentia immunochemotherapeutic drug for clinical treatment of EGFR-overexpressing tumors.

    See More

  1. Keywords:

External Sources

  1. View record in Web of Science®
  2. WOS: 000250308700036

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel